-
Amgen Receives CHMP Positive Opinion for XGEVA in the European Union
Friday, May 20, 2011 - 7:30am | 125Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal...
-
European Medicines Agency's Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Friday, May 20, 2011 - 7:25am | 56Biogen Idec (NASDAQ: BIIB) announced today that FAMPYRA has been granted a positive opinion for conditional approval from the European Medicines Agency's Committee for Medicinal Products for Human Use. Based on the CHMP recommendation, Biogen Idec expects that a marketing authorisation for FAMPYRA...
-
UPDATE: Citadel Upgrades United Therapeutics to Add (UTHR)
Friday, May 20, 2011 - 7:25am | 127Citi is out with its report today on United Therapeutics (NASDAQ: UTHR), upgrading UTHR from Neutral to Add. In a note to clients, Citi writes, "We are upgrading UTHR to Add (from Neutral) and raising our 12-month price target to $70 (from $65) based on our expectations for a positive outcome from...
-
UPDATE: Citadel Downgrades Savient Pharmaceuticals to Neutral
Friday, May 20, 2011 - 7:21am | 171Citadel is out with its report today on Savient Pharmaceuticals (NASDAQ: SVNT), downgrading SVNT to Neutral. In a note to clients, Citadel writes, "With the slow ramp for Krystexxa in the U.S., and with a lack of meaningful catalysts until late 2011 / early 2012, we are downgrading SVNT shares to...
-
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA
Friday, May 20, 2011 - 7:05am | 73GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion, recommending marketing authorisation for BENLYSTA as an add-on therapy in adult patients with...
-
Citadel Upgrades UTHR To Add, Raises PT To $70
Friday, May 20, 2011 - 6:18am | 28Citadel Securities has upgraded United Therapeutics Corporation (NASDAQ: UTHR) from Neutral to Add and has raised the price target to $70.
-
Citadel Downgrades Savient Pharmaceuticals To Neutral, $9 PT
Friday, May 20, 2011 - 6:17am | 26Citadel Securities has downgraded Savient Pharmaceuticals (NASDAQ: SVNT) from Buy to Neutral and has established a $9 price target.
-
ImmunoGen Announces Proposed Public Offering of Common Stock
Thursday, May 19, 2011 - 4:03pm | 103ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it intends to offer shares if its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size...
-
Positive Rumors About Cubist Pharmaceuticals Circulate (CBST)
Thursday, May 19, 2011 - 2:40pm | 96Unconfirmed positive rumors circulating at Cubist Pharmaceuticals (Nasdaq: CBST). Hearing takeover chatter http://www.telegraph.co.uk/finance/markets/marketreport/8524680/Astra-rumoured-to-be-eyeing-up-US-target.html This article may include mentions of rumors, chatter, or unconfirmed information...
-
Daily Long and Short Setup
Thursday, May 19, 2011 - 11:24am | 177The market definitely puked on the Existing Home Sales report, but the damage isn't all that bad from a daily perspective - it's just that it wiped out our early gains quite convincingly. Nonetheless, I am still focused on trading to the long side and will continue to do so, until this market...
-
Options Brief: Pharmacyclics Inc. (PCYC)
Thursday, May 19, 2011 - 10:26am | 74Shares of Pharmacyclics Inc. (NASDAQ: PCYC) are higher on the session by 6.44%, trading at $7.11. Overall put volume is now running at 17.44x the daily average, with 0% of all puts traded being purchases on the offer. 7,500 contracts have traded on the session so far. Pharmacyclics Inc. is a...
-
CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in Russia
Thursday, May 19, 2011 - 10:09am | 162CEL-SCI Corporation (NYSE: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia...
-
Luna Innovations and Hansen Medical Expand Development Work
Thursday, May 19, 2011 - 9:39am | 180Luna Innovations Incorporated (NASDAQ: LUNA) announced today that it will expand its product development efforts under its development and supply agreement with Hansen Medical, Inc., to continue integrating Luna's shape sensing technology into Hansen's medical robotic products. In December 2009,...
-
Nanosphere to Release Positive Pilot Study Data for Ultra-Sensitive Protein Cancer Biomarkers in Conjunction With the American Society of Clinical Oncology 2011 Annual Meeting
Thursday, May 19, 2011 - 9:37am | 85Nanosphere, Inc. (Nasdaq: NSPH) announced today that it will release early stage research data on potential cancer biomarkers requiring high sensitivity in an abstract for the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from June 3 to 7, 2011. The early...
-
Metabolix Prices Common Stock Offering of 6.2M Shares at $7.25 per Share
Thursday, May 19, 2011 - 9:18am | 87Metabolix, Inc. (NASDAQ: MBLX) today announced that it has priced a public offering of 6,200,000 newly issued shares of its common stock at a public offering price of $7.25 per share. The gross proceeds to Metabolix, before underwriting discounts and commissions and other offering expenses, from...